Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose Ketamine for Acute SI in Mood Disorders
NCT04099771Phase 1Unknown
- Sponsor
- The Miriam Hospital
- Start
- Jul 2019
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ketamine in suicidal ideation and major depressive disorder (MDD), sponsored by The Miriam Hospital. Primary endpoints: Number and Rate of Participants Recruited into the Study at 1 year, Completion of total infusion of ketamine by participants at 1 year and 1 more. Status: unknown.
02
Drugs
ketamine
03
Conditions
suicidal ideationmajor depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04099771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04099771.